Animal models of amyloidosis and tau allow for investigations into the potential contributions of PGRN to AD pathology and suggest that decreased levels of PGRN play a role in Aβ aggregation, increased tau phosphorylation, and complement activation [72,160,161]. The gene discussed is MAPT; the disease is Alzheimer disease.